DBV Technologies Advances Peanut Allergy Program With FDA Support On Pediatric Studies
Portfolio Pulse from Vandana Singh
DBV Technologies has received FDA support for its COMFORT Toddlers and COMFORT Children supplemental safety studies for peanut allergies. The studies will enroll children aged 1-7 years and aim to support the efficacy results from the EPITOPE and VITESSE Phase 3 pivotal studies. The company reported Q2 sales of $2.28 million, up from $1.53 million a year ago, and an EPS loss of $(0.26), down from $(0.35) a year ago. DBVT shares are up 8.11% at $1.60 during the premarket session.
August 01, 2023 | 2:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DBV Technologies has received FDA support for its peanut allergy studies, reported increased Q2 sales, and a reduced EPS loss. Its shares are up 8.11% in premarket trading.
The FDA support for DBV Technologies' studies is a positive development, indicating regulatory approval for the company's research. This, combined with the reported increase in Q2 sales and reduced EPS loss, is likely to boost investor confidence, leading to the rise in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100